Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology

BHARAT IMMUNOLOGICALS & BIOLOG

Healthcare › Pharmaceuticals & Biotechnology
₹8.78
at close · 28 Oct 2026
▼ 0.51 (-5.49%)

Latest filings

  1. BSE seeks clarification on significant price movement · Regulatory & Legal
  2. Government approves closure of BIBCOL · Regulatory & Legal
All filings ↓
Ask Nexa about BHARAT IMMUNOLOGICALS & BIOLOG

Snapshot

What the business is, and whether it's a good one at a fair price.

A Pharmaceuticals & Biotechnology company listed on BSE, reporting revenue of ₹69 Cr over the trailing twelve months.

Market Cap
₹38 Cr
P / E (TTM)
—
EV / EBITDA
—
Div Yield
—
Growth
—·
Revenue 5y CAGR
PAT — · EBITDA —
Quality
-19.9%·
ROCE (FY19)
ROE -19.1% · margin -7.5%
Leverage
0.00·
Debt / Equity · low
Net debt ₹80 Cr
Moves on a normal day
1.15%·
Median daily move
Last 267 sessions · the yardstick for filing-day moves
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/B#7/163
ROCE#169/183
ROE#153/166
Debt / Equity#151/166
Revenue growth#157/161
Profit growth#153/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY19 — not investment advice

Strengths
Nothing stands out in the filed numbers.
Concerns
Negative returns on capital — −19.9%
#169 of 183 in Pharmaceuticals on the latest reported figures
Carries more debt than its peers — 0.00× equity
higher than 91% of its 166 Pharmaceuticals peers
Heavy working capital — 185 days of cash tied up

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from BHARAT IMMUNOLOGICALS & BIOLOG's filed financials and exchange disclosures

What does BHARAT IMMUNOLOGICALS & BIOLOG do?

BHARAT IMMUNOLOGICALS & BIOLOG is a Pharmaceuticals & Biotechnology company listed on BSE.

Is BHARAT IMMUNOLOGICALS & BIOLOG profitable?

No. Over the trailing twelve months BHARAT IMMUNOLOGICALS & BIOLOG reported a net loss of ₹18 Cr on revenue of ₹69 Cr.

Is BHARAT IMMUNOLOGICALS & BIOLOG debt-free?

No. It reported borrowings of ₹80 Cr on its 30 Sept 2022 balance sheet, or net debt of ₹80 Cr after cash. Debt stands at 0.00× equity. That is higher than 91% of its 166 Pharmaceuticals peers.

How much does the BHARAT IMMUNOLOGICALS & BIOLOG share price move in a day?

On a typical session BHARAT IMMUNOLOGICALS & BIOLOG moves 1.15% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.

Where can I track BHARAT IMMUNOLOGICALS & BIOLOG's announcements?

Every NSE and BSE filing by BHARAT IMMUNOLOGICALS & BIOLOG appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.